ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 37, 2020 巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i6.20
70 pages

Pharmacodynamic Aspects of Modes of Drug Administration for Optimization of Drug Therapy

Amnon Hoffman
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O.B. 12065, Jerusalem 91120, Israel
David Stepensky
Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O.B. 12065, Jerusalem 91120, Israel

要約

Because of various pharmacodynamic properties, such as the nonlinearity of the concentration-effect relationship, activation of feedback homeostatic mechanisms, induction of pharmacodynamic tolerance, etc., administration of die same dose of drug by different modes is expected to produce different outcomes. This review clarifies the theoretical and practical aspects of the impact of different modes of drag administration on the magnitude of response, and hence on therapy outcomes. It discusses how the interrelationship between the pharmacodynamic properties and die drug input function affects die magnitude of response. To demonstrate this special dimension of drug therapy, relevant pharmacodynamic data was obtained for drugs with different therapeutic applications, including antibiotics, analgesics, diuretics, anti-cancer, anti-ulcer, anti-inflammatory, anti-hypertensive, lipid-lowering anti-parkinsonian, and immunosuppressive drugs. These examples provide guidelines for implementing the role of the mode of drug administration (including rate, schedule, and route of drug treatment) during drug development or optimization of drug therapy.


Articles with similar content:

Engineered PLGA Nanoparticles: An Emerging Delivery Tool in Cancer Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 1
Amit K. Jain, Manasmita Das, Nitin K. Swarnakar, Sanyog Jain
The Colon as a Possible Target for Orally Administered Peptide and Protein Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 6
Susan Moody Haupt, Abraham Rubinstein
Oral Absorption Promoters: Opportunities, Issues, and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 5
Sushilkumar Patil, Girish Kore, Atul Kolate, Chetan Yewale, Ambikanandan Misra
Mucosal Drug Delivery: Membranes, Methodologies, and Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 3
Bozena Michniak, Yifan Song, Rashmi Thakur, Victor M. Meidan, Yiping Wang
Approaches and Opportunities in Colon-Specific Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Abraham Rubinstein